Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 .
Mark J LevisMehdi HamadaniBrent R LoganRichard J JonesAnurag K SinghMark R LitzowJohn R WingardEsperanza B PapadopoulosAlexander E PerlRobert J SoifferCelalettin UstunMasumi Ueda OshimaGeoffrey L UyEdmund K WallerSumithra VasuMelham M SolhAsmita MishraLori S MufflyHee-Je KimJan-Henrik MikeschYuho NajimaMasahiro OnozawaKirsty ThomsonArnon NaglerAndrew H WeiGuido MarcucciNancy L GellerNahla HasabouDavid DelgadoMatt RosalesJason E HillStanley C GillRishita NuthethiDenise KingHeather WittsackAdam MendizabalSteven M DevineMary M HorowitzYi-Bin Chennull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.